Executive leadership to participate in upcoming investor and industry events to highlight Imbria’s differentiated approach to cardiac energetics and clinical development strategy

BOSTON, Mass., September 15, 2026 — Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that members of its executive leadership team will participate in several investor and industry conferences this fall, where they will discuss the Company’s corporate strategy, clinical development program, and the differentiated science behind ninerafaxstat, its investigational therapy for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

“Imbria is entering an important phase of execution as we continue advancing ninerafaxstat through clinical development and delivering against key objectives,” said Alvin Shih, MD, Chief Executive Officer of Imbria Pharmaceuticals. “We look forward to engaging with the investment and broader life sciences community to share the progress of our FORTITUDE-HCM Phase 2b trial, highlight the science behind cardiac energetics, and discuss our vision for advancing a potential new treatment option for patients living with symptomatic nHCM.”

Members of Imbria’s leadership team will participate in panel discussions and fireside chats at the following conferences:

13th Annual World Medical Innovation Forum

Date: September 22–23, 2026

Location: Boston, MA

Format: Panel discussion

Panel: Heart of the Matter | Redefining Cardiovascular Care Beyond Statins

Session Date and Time: Wednesday, September 23, 11:00–11:40 a.m. ET

Speaker: Alvin Shih, MD, Chief Executive Officer

Stifel 2026 Virtual Cardiometabolic Forum

Date: September 30, 2026

Location: Virtual

Format: Fireside chat

Session Date and Time: Wednesday, September 30, 3:00–3:25 p.m. ET

Speaker: Alvin Shih, MD, Chief Executive Officer

Canaccord 2026 Biotech Private Company Symposium

Date: October 13, 2026

Location: Virtual

Format: Fireside chat

Session Date and Time: Tuesday, October 13, 10:00–10:25 a.m. ET

Speaker: Albert Kim, MD, PhD, Chief Medical Officer